Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial.
about
Antigen-Specific Regulatory T Cells and Low Dose of IL-2 in Treatment of Type 1 DiabetesThe Physiology of Proinsulin C-Peptide: Unanswered Questions and a Proposed ModelDefining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus reportDisease modifying therapies in type 1 diabetes: Where have we been, and where are we going?Correlation Among Hypoglycemia, Glycemic Variability, and C-Peptide Preservation After Alefacept Therapy in Patients with Type 1 Diabetes Mellitus: Analysis of Data from the Immune Tolerance Network T1DAL Trial.A Practical Review of C-Peptide Testing in DiabetesRecommendations for the definition of clinical responder in insulin preservation studiesLow levels of C-peptide have clinical significance for established Type 1 diabetes.Future opportunities in diabetic retinopathy research.Comparison of Metabolic Outcomes in Children Diagnosed with Type 1 Diabetes Through Research Screening (Diabetes Autoimmunity Study in the Young [DAISY]) Versus in the Community.Interaction between peroxisome proliferator- activated receptor gamma polymorphism and overweight on diabetic retinopathy in a Chinese case-control study.Heterogeneity in recent-onset type 1 diabetes - a clinical trial perspectiveStrategies for clinical trials in type 1 diabetesPotential beneficial effects of a gluten-free diet in newly diagnosed children with type 1 diabetes: a pilot studyDiabetes at the crossroads: relevance of disease classification to pathophysiology and treatment.Revisiting multiple models of progression of β-cell loss of function in type 1 diabetes: Significance for prevention and cure.Implementing a Reference Measurement System for C-Peptide: Successes and Lessons Learned.An update on the potential role of C-peptide in diabetes and osteoporosis.Glucose targets for preventing diabetic kidney disease and its progression.Targeting orphan G protein-coupled receptors for the treatment of diabetes and its complications: C-peptide and GPR146.C-Peptide replacement therapy in type 1 diabetes: are we in the trough of disillusionment?Fall in C-Peptide During First 4 Years From Diagnosis of Type 1 Diabetes: Variable Relation to Age, HbA1c, and Insulin Dose.Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes.Most people with long-duration type 1 diabetes in a large population-based study are insulin microsecretors.Random non-fasting C-peptide testing can identify patients with insulin-treated type 2 diabetes at high risk of hypoglycaemia.Factors impeding the discovery of an intervention-based treatment for type 1 diabetes.The Predictive Factors for Diabetic Remission in Chinese Patients with BMI > 30 kg/m2 and BMI < 30 kg/m2 Are Different.Meta-genome-wide association studies identify a locus on chromosome 1 and multiple variants in the MHC region for serum C-peptide in type 1 diabetes.Association between low C-peptide and fragility fractures in postmenopausal women without diabetes.Residual beta-cell function in diabetes children followed and diagnosed in the TEDDY study compared to community controls.Artificial Pancreas or Novel Beta-Cell Replacement Therapies: a Race for Optimal Glycemic Control?
P2860
Q26770386-61CB7D5E-E4ED-46CF-94AD-4B17C76612C4Q27015746-82CB7786-3839-4EBA-9B49-C8E43C549790Q27687598-2FCE8C02-C735-4C98-85D2-B06759E20075Q28081034-FEECAA4C-651C-4E3B-B555-692E1F87F987Q31099230-A648D8AB-79A3-4B0D-9D6F-C699C701050FQ33732640-A06C8F12-F4DF-48DD-9740-48807FFBCC6FQ34077400-C7FE4297-00CA-498F-846B-876517E18A74Q34484912-BEB6D669-BA5A-4223-B424-01EF2C797DD1Q35935835-0FB7B129-1B0B-4396-ADBD-460FFE4BAA97Q36014076-362BEEE1-FAD6-4936-BB73-A15A7FCA9188Q36493240-7C78CF92-8750-4CC2-A1CD-5B2084E1A780Q36749719-718D4011-CB3F-460E-80A0-25A5277DACEEQ36995370-98F67DE5-0CA7-422B-A967-5DA45342DC62Q37075420-B36F6DB0-F5E1-4D02-A876-F9D4D847C580Q38615808-55EAB059-4858-4939-9D35-AFA8CD167EB5Q38692770-6AB9F5B3-3DFD-4143-801D-B6662A079156Q38711292-A03F2EAB-DF48-416F-8492-A591C242DC6DQ38735440-085F1CAD-1B20-47CB-8A7F-66D33EE973AFQ38736800-9A9DDA66-9106-4A4A-808D-B40FE41D45C2Q38866310-8D8BD2DD-C105-4444-A90C-6F12716C5614Q39420435-423CAE77-A8E4-4224-9E86-ABA0DC983F2BQ39596760-018BD333-F4A9-4AB5-85B1-BB6D3FA99D68Q40088521-35DC6B47-0764-47E9-A8D9-8436AA695D94Q42380027-E6120725-E2D5-40D3-913F-6EBBB1EC0BE8Q47567739-9E47430A-C260-481F-9DD7-03D74C52F485Q48480363-BCEC39EB-6EF1-470A-BC20-4BF85E997C6FQ50041519-EAAE4837-9133-48E3-903A-5284CC218342Q50060749-3E7474C7-D80F-4DD5-A15A-9CD9778B6B5DQ51829054-80A6F34D-7D91-40E6-B0C2-C62C4910B9F8Q52798088-BAE5F60E-5EE7-4D60-B5DD-5A037C0BD524Q58701212-8184A4AE-39F4-49DD-9A42-19CD0C39C7A7
P2860
Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial.
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Impact of C-peptide preservati ...... ntrol and Complications Trial.
@ast
Impact of C-peptide preservati ...... ntrol and Complications Trial.
@en
type
label
Impact of C-peptide preservati ...... ntrol and Complications Trial.
@ast
Impact of C-peptide preservati ...... ntrol and Complications Trial.
@en
prefLabel
Impact of C-peptide preservati ...... ntrol and Complications Trial.
@ast
Impact of C-peptide preservati ...... ntrol and Complications Trial.
@en
P2093
P2860
P356
P1433
P1476
Impact of C-peptide preservati ...... ntrol and Complications Trial.
@en
P2093
DCCT/EDIC Research Group
Jerry P Palmer
Paula McGee
P2860
P304
P356
10.2337/DB13-0881
P407
P577
2013-10-02T00:00:00Z